Nanoflowers as Next Generation Catalysts

Nanoflowers are nanostructures which, when viewed with scanning electron microscopy, resemble flowers or trees. They are of interest to scientists because of their high stability and enhanced efficiency. Their applications range from optoelectronics devices or sensors, catalysis and solar cells as well as uses in nanotechnology. Associate Professor İsmail Öçsoy is a teacher and researcher... Read more

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy

With hypomethylating agents significantly improved complete response rates in certain adults with newly diagnosed acute myeloid leukaemia In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall survival rate of less than 10%1 Study data reinforces the potential of... Read more

Consolidated Financial Statements for the Year Ended March 31, 2021 FY2021 (April 1, 2020 – March 31, 2021) [UNAUDITED]

This article is translated from press release in Japanese for your convenience. Forward-Looking Statements Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management... Read more

PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing WALTHAM, Mass.–(BUSINESS WIRE)–May 12, 2021– PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash. The transaction is expected to close... Read more

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer

Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancer Studies in personalised healthcare exploring tumour agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualised treatment plans New data, and drug combination strategies for the treatment of lymphoma from the largest... Read more

Brooks Automation Reports Results of Second Quarter of Fiscal 2021, Ended March 31, 2021, and Announces Quarterly Cash Dividend

Brooks Automation Reports Results of Second Quarter of Fiscal 2021, Ended March 31, 2021, and Announces Quarterly Cash Dividend Record Revenue and Continued Margin Expansion in Both Life Sciences and Semiconductor Solutions CHELMSFORD, Mass., May 10, 2021 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq: BRKS) today reported financial results for the second fiscal quarter of 2021,... Read more

BD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance

FRANKLIN LAKES, N.J., May 6, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021.  This represents an increase of 15.4% over the prior-year period on a reported basis and was driven by the contribution of... Read more

Thin Film Fracture Toughness and Focused Ion Beam (FIB) Milling

Dr. Benoit Merle is a group leader and faculty member with the University of Erlangen-Nuremberg in the Department of Materials Science and Engineering. He is a lecturer, mentor to graduate students and manages the nanomechanical research lab. We interviewed Dr. Merle about his recent publication, which investigated focused ion beam (FIB) milling and fracture toughness... Read more

Bruker Reports First Quarter 2021 Financial Results

Q1 2021 revenue growth of 30.8% year-over-year, organic revenue growth of 23.8% Q1 2021 GAAP EPS of $0.37; non-GAAP EPS of $0.44, compared to $0.14 in Q1 2020 Raising fiscal year 2021 outlook on strong demand for the Company’s high-performance life science tools, scientific instruments and diagnostic solutions BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR)... Read more

PerkinElmer Announces Financial Results for the First Quarter of 2021

Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings Guidance WALTHAM, Mass.–(BUSINESS WIRE)–May 4, 2021– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for... Read more